OMGA vs. SGMO, KPTI, MOLN, CMRX, PSNL, EDIT, OCGN, VYGR, TCRX, and ALVO
Should you be buying Omega Therapeutics stock or one of its competitors? The main competitors of Omega Therapeutics include Sangamo Therapeutics (SGMO), Karyopharm Therapeutics (KPTI), Molecular Partners (MOLN), Chimerix (CMRX), Personalis (PSNL), Editas Medicine (EDIT), Ocugen (OCGN), Voyager Therapeutics (VYGR), TScan Therapeutics (TCRX), and Alvotech (ALVO). These companies are all part of the "medical" sector.
Sangamo Therapeutics (NASDAQ:SGMO) and Omega Therapeutics (NASDAQ:OMGA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations, community ranking and valuation.
Sangamo Therapeutics received 416 more outperform votes than Omega Therapeutics when rated by MarketBeat users. However, 71.88% of users gave Omega Therapeutics an outperform vote while only 62.71% of users gave Sangamo Therapeutics an outperform vote.
Sangamo Therapeutics has a net margin of -1,749.06% compared to Sangamo Therapeutics' net margin of -1,868.35%. Sangamo Therapeutics' return on equity of -136.04% beat Omega Therapeutics' return on equity.
Sangamo Therapeutics presently has a consensus price target of $5.67, indicating a potential upside of 904.02%. Omega Therapeutics has a consensus price target of $10.00, indicating a potential upside of 405.05%. Given Omega Therapeutics' higher possible upside, research analysts plainly believe Sangamo Therapeutics is more favorable than Omega Therapeutics.
56.9% of Sangamo Therapeutics shares are held by institutional investors. Comparatively, 97.5% of Omega Therapeutics shares are held by institutional investors. 2.8% of Sangamo Therapeutics shares are held by insiders. Comparatively, 57.0% of Omega Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
In the previous week, Sangamo Therapeutics and Sangamo Therapeutics both had 3 articles in the media. Omega Therapeutics' average media sentiment score of 0.82 beat Sangamo Therapeutics' score of 0.62 indicating that Sangamo Therapeutics is being referred to more favorably in the media.
Sangamo Therapeutics has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500. Comparatively, Omega Therapeutics has a beta of 1.99, indicating that its stock price is 99% more volatile than the S&P 500.
Omega Therapeutics has lower revenue, but higher earnings than Sangamo Therapeutics. Omega Therapeutics is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Omega Therapeutics beats Sangamo Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Omega Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for OMGA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OMGA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Omega Therapeutics Competitors List
Related Companies and Tools
